Ontology highlight
ABSTRACT:
SUBMITTER: Spellberg B
PROVIDER: S-EPMC5242400 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Spellberg B B Marr K A KA Brass E P EP
Clinical pharmacology and therapeutics 20161014 6
In 2002, Shlaes and Moellering warned that pharmaceutical companies were abandoning antibiotic research and development due to changing regulatory standards regarding noninferiority (NI) clinical trials. NI trials are subject to unique biases that may yield false-positive conclusions. The US Food and Drug Administration (FDA) developed guidance to ensure that NI results truly reflect drug efficacy. These changes, intended to reduce uncertainty in trial results, have shaped trial enrollment and c ...[more]